Tag: locally advanced pancreatic cancer market size

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Projected Valuation Of The Locally Advanced Pancreatic Cancer Market In The Coming Years?

The market size for locally advanced pancreatic cancer has recently witnessed swift expansion. It is anticipated to increase from $0.95 billion in 2024 to $1.05 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.6%. The historical growth in this sector can be credited to a heightened awareness about pancreatic cancer, advancements in chemotherapy processes, increased utilisation of targeted therapies, escalating incidence of pancreatic cancer, the evolution of combination treatment methodologies, and bettered options for supportive care.

In the upcoming years, rapid expansion is projected for the locally advanced pancreatic cancer market, with forecasts indicating a growth to $1.56 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.4%. Contributing factors for this predicted growth include heightened awareness about pancreatic cancer, betterments in chemotherapy regimens, increased application of targeted therapies, a surge in pancreatic cancer cases, introduction of combination treatment methods, and improved supportive care alternatives. During the forecasted period, the main trends to influence the market include the progress in immunotherapy, the evolution of targeted therapies, refinement of precision radiation strategies, enhancement of diagnostic imaging, inclination towards minimally invasive surgeries, application of artificial intelligence in devising treatment strategies, and advancements in combination therapy.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Locally Advanced Pancreatic Cancer Market?

The rise in the usage of tobacco is anticipated to fuel the expansion of the marketplace for locally advanced pancreatic cancer. Tobacco, a plant whose leaves form the basis of products like cigarettes and cigars, contains an addictive substance, nicotine. This substance is associated with grave health problems including cancer and heart disease. The surge in tobacco usage is propelled by factors including easy availability, low-cost, advertising of tobacco products, societal endorsement in some regions, and stress-induced smoking. The use of tobacco is a substantial risk component in the formation of locally advanced pancreatic cancer, leading to a higher occurrence of pancreatic cancers. For instance, the Global Action to End Smoking, an American not-for-profit organization focusing on research to curb the smoking crisis, reported in January 2024 that an estimated 62.9 million adults in the U.S. were tobacco users in 2022. This figure placed the U.S. 4th globally and 1st in the Americas in terms of tobacco consumption. They also noted that around 11.5% of American adults (roughly 28.3 million people) were cigarette smokers and the percentage was higher in males (13.1%) as compared to females (10.1%). Thus, the escalation in tobacco use is a key factor propelling the growth of the locally advanced pancreatic cancer industry.

Which Sub-Segments Are Driving Growth Within The Locally Advanced Pancreatic Cancer Market?

The locally advanced pancreatic cancermarket covered in this report is segmented –

1) By Therapy: Chemotherapy; Immunotherapy; Radiation Therapy; Surgery

2) By Route Of Administration: Oral; Injectables; Other Route Of Administrations

3) By End-User: Hospital; Specialty Clinics; Research Institutions; Other End-Users

Subsegments:

1) By Chemotherapy: Gemcitabine-based Chemotherapy; FOLFIRINOX Chemotherapy

2) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines

3) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy (SBRT)

4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure); Distal Pancreatectomy; Total Pancreatectomy

What Key Trends Are Driving Growth In The Locally Advanced Pancreatic Cancer Market?

Companies in the locally advanced pancreatic cancer market are turning to orphan drug development to improve therapy choices and meet the needs of patients with this aggressive disease. Orphan drugs are aimed at treating rare conditions and are supported by incentives like tax benefits and market exclusivity. In January 2025, US-based Actuate Therapeutics Inc. announced that its GSK-3ß inhibitor Elraglusib had received Orphan Drug Designation from both the FDA and EMA for the treatment of pancreatic ductal adenocarcinoma (PDAC). This designation follows strong Phase 2 trial results, highlighting the drug’s promise in treating advanced PDAC.

Which Players Are Shaping The Competitive Landscape Of The Locally Advanced Pancreatic Cancer Market?

Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

How Do Regional Dynamics Influence The Locally Advanced Pancreatic Cancer Market Performance?

North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21214&type=smp

Browse Through More Reports Similar to the Global Locally Advanced Pancreatic Cancer Market 2025, By The Business Research Company

Pancreatic Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Pancreatic Cancer Diagnostic Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Locally Advanced Pancreatic Cancer Market Size Likely To Evolve From 2025 Through 2034?

The market for locally advanced pancreatic cancer has experienced rapid growth in recent years. It is projected to expand from $0.95 billion in 2024 to $1.05 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.6%. This historical increase can be attributed to several factors, including heightened awareness of pancreatic cancer, advancements in chemotherapy regimens, a rise in the adoption of targeted therapies, an increase in the incidence of pancreatic cancer, the formulation of combination treatment protocols, and enhanced supportive care options.

The market size for locally advanced pancreatic cancer is anticipated to experience substantial growth over the coming years. It is projected to expand to $1.56 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 10.4%. This expansion during the forecast period can be attributed to increased awareness of pancreatic cancer, advancements in chemotherapy regimens, a rise in the adoption of targeted therapies, an uptick in the incidence of pancreatic cancer, the formulation of combination treatment protocols, and improvements in supportive care options. Significant trends expected during this period include breakthroughs in immunotherapy, the continued development of targeted therapies, more sophisticated precision radiation techniques, enhanced diagnostic imaging, the integration of minimally invasive surgical approaches, the incorporation of artificial intelligence into treatment planning, and ongoing progress in combination therapy.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

What Are The Top Growth Drivers Impacting The Locally Advanced Pancreatic Cancer Market Outlook?

The escalating use of tobacco is anticipated to stimulate the expansion of the locally advanced pancreatic cancer markets moving forward. Tobacco is a plant whose leaves are processed into items such as cigarettes and cigars. It contains nicotine, an addictive substance linked to serious health problems like cancer and heart disease. The uptick in tobacco consumption is fueled by factors including simple availability, affordability, tobacco industry marketing, social acceptance in certain regions, and stress-induced smoking. Tobacco consumption represents a significant risk factor for the onset of locally advanced pancreatic cancer, as it contributes to a higher incidence of pancreatic malignancies. For example, in January 2024, data from Global Action to End Smoking, a US-based non-profit organization dedicated to research on ending the smoking epidemic, indicated that in 2022, approximately 62.9 million adults in the U.S. utilized tobacco, placing it 4th globally and 1st in the Americas. Furthermore, about 11.5% of U.S. adults (28.3 million) smoked cigarettes, with males exhibiting higher rates (13.1%) than females (10.1%). Consequently, the increase in tobacco consumption is a key driver for the growth of the locally advanced pancreatic cancer market.

What Are The Major Segments Identified In The Locally Advanced Pancreatic Cancer Market?

The locally advanced pancreatic cancermarket covered in this report is segmented –

1) By Therapy: Chemotherapy; Immunotherapy; Radiation Therapy; Surgery

2) By Route Of Administration: Oral; Injectables; Other Route Of Administrations

3) By End-User: Hospital; Specialty Clinics; Research Institutions; Other End-Users

Subsegments:

1) By Chemotherapy: Gemcitabine-based Chemotherapy; FOLFIRINOX Chemotherapy

2) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines

3) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy (SBRT)

4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure); Distal Pancreatectomy; Total Pancreatectomy

How Are Emerging Market Trends Shaping The Locally Advanced Pancreatic Cancer Industry Landscape?

Leading companies active in the locally advanced pancreatic cancer market are focusing their strategies on developing innovative therapeutic products, such as orphan drugs, designed to expand treatment options, improve patient outcomes, and address the significant unmet medical needs associated with this aggressive disease. These specialized orphan drugs are developed to treat rare conditions affecting a small patient population and benefit from incentives provided by authorities, including tax reductions and market exclusivity, to encourage their creation. A relevant example occurred in January 2025, when Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its compound, Elraglusib, a novel GSK-3β inhibitor, had been granted Orphan Drug Designation by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for its use in treating pancreatic ductal adenocarcinoma (PDAC), a type of locally advanced pancreatic cancer. This recognition underscores its potential to fill a critical treatment gap for this severe cancer, especially following promising Phase 2 trial results that showed significant clinical improvements and anti-tumor effects in patients with metastatic PDAC.

Which Key Players Are Driving Competition In The Locally Advanced Pancreatic Cancer Market?

Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

Which Regional Markets Are Contributing Most To The Locally Advanced Pancreatic Cancer Industry Expansion?

North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Locally Advanced Pancreatic Cancer Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21214&type=smp

Browse Through More Reports Similar to the Global Locally Advanced Pancreatic Cancer Market 2025, By The Business Research Company

Pancreatic Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Pancreatic Cancer Diagnostic Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Projected CAGR for the Locally Advanced Pancreatic Cancer Market Size from 2025 to 2034?

The market size for locally advanced pancreatic cancer has seen swift expansion in the past few years. Projections show an upward trend from $0.95 billion in 2024 to $1.05 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.6%. The escalation in the historical timeframe is primarily due to heightened consciousness about pancreatic cancer, advancement in chemotherapy treatments, burgeoning utilization of targeted therapies, an upward trend in the occurrence of pancreatic cancer, progress in developing combined treatment procedures, and better options for supportive care.

Expectations for the locally advanced pancreatic cancer market reveal a significant expansion aligned for the upcoming years, with projections indicating growth to reach$1.56 billion by 2029 at a compound annual growth rate (CAGR) of 10.4%. The surge predicted throughout this period can be credited to several factors including heightened consciousness about pancreatic cancer, enhancements in chemotherapy regimens, more extensive usage of targeted treatment methods, increased occurrence of pancreatic cancer, the creation of combined treatment guidelines, and improved options for supportive care. Key developments anticipated during this period encompass progress in immunotherapy, the creation of targeted treatments, the evolution of precision radiation methodologies, superior diagnostic imaging, the use of minimally invasive surgical techniques, the implementation of artificial intelligence in treatment strategies, and breakthroughs in combined therapy strategies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

What Are the Core Market Drivers Propelling Growth in the Locally Advanced Pancreatic Cancer Industry?

The growth of markets for locally advanced pancreatic cancer is projected to be spurred by an upsurge in tobacco use. Utilized primarily in products like cigarettes and cigars, tobacco is a plant that contains an addictive ingredient known as nicotine, linking it to serious health concerns such as cancer and heart disease. The escalate in tobacco use has roots in various factors like broad access, cost-effectiveness, marketing of tobacco, social acceptance in certain regions, and stress-induced smoking. Consumption of tobacco significantly contributes to the risk of developing locally advanced pancreatic cancer, hence leading to a higher incidence of pancreatic malignancies. To illustrate, data from the US-based non-profit organization, Global Action to End Smoking, that conducts research aimed at terminating the smoking epidemic indicated that in 2022, around 62.9 million adult tobacco consumers lived in the U.S. This places the U.S. as the 4th global rank and first in the Americas. Moreover, about 11.5% adulte population of the U.S. (28.3 million) smoked cigarettes, with male smokers (13.1%) outnumbering female smokers (10.1%). Consequently, as tobacco consumption escalates, so does the growth of the locally advanced pancreatic cancer market.

How Is the Locally Advanced Pancreatic Cancer Market Segmented?

The locally advanced pancreatic cancermarket covered in this report is segmented –

1) By Therapy: Chemotherapy; Immunotherapy; Radiation Therapy; Surgery

2) By Route Of Administration: Oral; Injectables; Other Route Of Administrations

3) By End-User: Hospital; Specialty Clinics; Research Institutions; Other End-Users

Subsegments:

1) By Chemotherapy: Gemcitabine-based Chemotherapy; FOLFIRINOX Chemotherapy

2) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines

3) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy (SBRT)

4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure); Distal Pancreatectomy; Total Pancreatectomy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21214&type=smp

Which Regions Are Driving the Next Phase of the Locally Advanced Pancreatic Cancer Market Growth?

North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Locally Advanced Pancreatic Cancer Industry?

The locally advanced pancreatic cancer market is witness to leading corporations actively working towards the creation of innovative merchandise, such as orphan drugs. The objective is to augment the treatment variety, better patient results, and address the unfulfilled medical requirements connected with this harsh illness. Orphan drugs are specifically constructed to cure rare illnesses that impact a minor population and are incentivized by governmental bodies via benefits like tax deductions and market exclusivity to encourage their growth. To illustrate, Actuate Therapeutics Inc., an American biopharmaceutical enterprise, declared in January 2025, that its creation Elraglusib, a fresh GSK-3ß inhibitor, has earned Orphan Drug Designation from the European Medicines Agency (EMA) and US Food and Drug Administration (FDA). This is for the treatment of pancreatic ductal adenocarcinoma (PDAC) (a probable type of locally advanced pancreatic cancer). This acknowledgment underlines its potential to bridge a crucial gap in the treatment of this severe cancer, especially after the promising Phase 2 trials demonstrated significant clinical advancements and anti-tumor impacts in metastatic PDAC patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

How Is the Locally Advanced Pancreatic Cancer Market Defined and What Are Its Core Parameters?

Locally advanced pancreatic cancer (LAPC) refers to a stage of pancreatic cancer where the tumor is confined to the pancreas and surrounding tissues but has not spread to distant organs. This cancer is usually not suitable for surgical removal due to its involvement with vital blood vessels or nearby structures.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21214

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Locally Advanced Pancreatic Cancer Market Size Changed, over the years?

The market size for locally advanced pancreatic cancer has seen a quick expansion in recent times. Expected to rise from $0.95 billion in 2024 to $1.05 billion in 2025, the market will have a compound annual growth rate (CAGR) of 10.9%. The escalation during the historic period is due to factors such as increased awareness of pancreatic cancer, advanced chemotherapy procedures, escalated usage of targeted therapies, a surge in pancreatic cancer cases, the evolution of combination treatment protocols, and improved supportive care alternatives.

How Much Will the Locally Advanced Pancreatic Cancer Market Be Worth in 2029?

In the coming years, a swift expansion is anticipated in the market size of locally advanced pancreatic cancer, projected to reach $1.57 billion by 2029, according to a compound annual growth rate (CAGR) of 10.5%. This growth during the forecast period can be ascribed to heightened awareness of pancreatic cancer, advancements in chemotherapy regimens, increased application of targeted therapies, a rise in pancreatic cancer incidence, the creation of combination treatment plans, and the improved care alternatives available. Key trends expected in the forecast timeframe include progress in immunotherapy, the introduction of targeted therapies, advancements in precise radiation methods, improved diagnostic imaging, the uptake of minimal invasive surgery, the use of artificial intelligence in treatment design, and progression in combination therapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

Which is the Largest Company in the Locally Advanced Pancreatic Cancer Market?

Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co

What Are the Main Market Drivers in the Locally Advanced Pancreatic Cancer Industry?

The rise in tobacco use is forecasted to fuel the growth of the market for locally advanced pancreatic cancer. Tobacco, a plant whose leaves are processed for consumption in items like cigarettes and cigars, is loaded with nicotine – an addictive substance linked to severe health conditions like cancer and heart diseases. Various factors such as easy availability, affordability, product promotion, and social acceptance in some places, as well as stress-driven smoking, propel the surge in tobacco use. This increase in tobacco intake is a primary risk influencer for locally advanced pancreatic cancer, contributing to the escalated occurrence of pancreatic abnormalities. For example, as per the Global Action to End Smoking, a US-based non-profit focused on research to halt the smoking epidemic, in 2022, nearly 62.9 million adults in the U.S were tobacco users, putting it at 4th place worldwide and at the top in the Americas. Furthermore, about 11.5% of American adults, which is approximately 28.3 million people smoked cigarettes, with a higher percentage seen in males (13.1%) compared to females (10.1%). As a result, the rise in tobacco use is a key driver propelling the growth of the locally advanced pancreatic cancer market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21214&type=smp

How Is the Locally Advanced Pancreatic Cancer Market Segments Structured?

The locally advanced pancreatic cancer market covered in this report is segmented –

1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Surgery

2) By Route Of Administration: Oral, Injectables, Other Route Of Administrations

3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users

Subsegments:

1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy

2) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines

3) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)

4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure), Distal Pancreatectomy, Total Pancreatectomy

What Strategic Trends Are Transforming the Locally Advanced Pancreatic Cancer Market?

Key players in the locally advanced pancreatic cancer market are concentrating on the creation of innovative products like orphan drugs, with the aim of bettering treatment alternatives, boosting patient results, and satisfying the unaddressed medical requirements tied to this aggressive disease. Orphan drugs, made for the treatment of rare ailments affecting a smaller population, are encouraged by regulatory bodies through benefits such as tax deductions and market exclusivity for their development. For instance, in January 2025, Actuate Therapeutics Inc., a biopharmaceutical firm in the US, declared that Elraglusib, its new GSK-3β inhibitor, obtained Orphan Drug Designation from both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC), which is a potential type of locally advanced pancreatic cancer. This distinction represents its potential to deal with a significant gap in treating this type of severe cancer, particularly after successful Phase 2 trial outcomes demonstrated considerable clinical progress and anti-tumor effects in patients with metastatic PDAC.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

Which Global Regions Offer the Highest Growth in the Locally Advanced Pancreatic Cancer Market?

North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21214

This Report Delivers Insight On:

1. How big is the locally advanced pancreatic cancer market, and how is it changing globally?

2. Who are the major companies in the locally advanced pancreatic cancer market, and how are they performing?

3. What are the key opportunities and risks in the locally advanced pancreatic cancer market right now?

4. Which products or customer segments are growing the most in the locally advanced pancreatic cancer market?

5. What factors are helping or slowing down the growth of the locally advanced pancreatic cancer market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Current and Projected Market Size of the Locally Advanced Pancreatic Cancer Market Through 2034?

The market for locally advanced pancreatic cancer has experienced significant expansion in the past few years. It is projected to escalate from $0.95 billion in 2024 to $1.05 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.9%. Factors contributing to the growth during the historic period include heightened awareness of pancreatic cancer, improved chemotherapy treatment plans, an uptick in the use of targeted therapies, an increase in pancreatic cancer incidence rates, the creation of more effective combination treatment protocols, and greater options for supportive care.

The market size of locally advanced pancreatic cancer is set to experience a significant spike in growth in the coming years, blooming to a market value of $1.57 billion by 2029 with a CAGR of 10.5%. This surge within the forecast period can be associated with the rising awareness towards pancreatic cancer, refinement of chemotherapy courses, the increased usage of targeted therapies, escalation in pancreatic cancer occurrences, the progression of combination treatment plans, and the improvement of supportive care alternatives. The forecast period will also witness vital trends such as breakthroughs in immunotherapy, the establishment of targeted therapies, enhancement in precision radiation methodologies, betterment in diagnostic imaging, the adoption of non-invasive surgical techniques, the inclusion of artificial intelligence in devising treatment plans, and advancements in combination therapy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Locally Advanced Pancreatic Cancer Market?

The growth of the market for locally advanced pancreatic cancer is expected to be propelled by the rising tobacco usage. Tobacco – a plant utilized in products such as cigars and cigarettes – contains nicotine, an addictive substance proven to cause severe health problems like cancer and cardiovascular disease. Factors like easy accessibility, affordability, promotion of tobacco products, social acceptance in certain areas, and smoking due to stress are contributing to the increased use of tobacco. This increase is directly related to the significant risk it poses for developing locally advanced pancreatic cancer due to its contribution to the heightened incidence of pancreatic malignancies. The US-based non-profit organization, Global Action to End Smoking, reported in January 2024 that approximately 62.9 million U.S. adults used tobacco in 2022, giving the U.S. a global ranking of 4th and 1st in the Americas. Furthermore, about 11.5% of U.S. adults (28.3 million) were cigarette smokers, with a higher proportion of males (13.1%) than females (10.1%) indulging in smoking. Therefore, the surge in tobacco usage is fueling the expansion of the locally advanced pancreatic cancer market.

Which Primary Segments of the Locally Advanced Pancreatic Cancer Market Are Driving Growth and Industry Transformations?

The locally advanced pancreatic cancer market covered in this report is segmented –

1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Surgery

2) By Route Of Administration: Oral, Injectables, Other Route Of Administrations

3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users

Subsegments:

1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy

2) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines

3) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)

4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure), Distal Pancreatectomy, Total Pancreatectomy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21214&type=smp

Which Regions Are Key Players in the Growth of the What Are the Primary Drivers Supporting the Market Growth of the Locally Advanced Pancreatic Cancer Market? Market?

North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Locally Advanced Pancreatic Cancer Market?

Key players in the locally advanced pancreatic cancer market are concentrating on the creation of novel products such as orphan drugs, with the aim of expanding treatment choices, improving patient outcomes, and meeting the unresolved healthcare needs related to this serious condition. Orphan drugs, designed to address rare diseases impacting a small populace, receive support from regulatory bodies through tax cuts and assured market exclusivity to encourage their creation. For example, in January 2025, Actuate Therapeutics Inc., a biopharmaceutical firm based in the United States, reported that Elraglusib, its new GSK-3ß inhibitor, had been granted Orphan Drug Designation by both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC) – a potential type of locally advanced pancreatic cancer. This designation underscores its potential to address a crucial gap in the treatment of this extreme form of cancer, primarily following promising results from Phase 2 trials demonstrating significant clinical progress and anti-cancer effects in patients with metastatic PDAC.

View the full report here:

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

What Parameters Are Used to Define the Locally Advanced Pancreatic Cancer Market?

Locally advanced pancreatic cancer (LAPC) refers to a stage of pancreatic cancer where the tumor is confined to the pancreas and surrounding tissues but has not spread to distant organs. This cancer is usually not suitable for surgical removal due to its involvement with vital blood vessels or nearby structures.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21214

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the locally advanced pancreatic cancer market?

In recent times, there has been a swift expansion in the market size for locally advanced pancreatic cancer. Predictions indicate that it may expand from $0.95 billion in 2024 to $1.05 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.9%. This notable development during the historic period can be linked to factors such as heightened awareness about pancreatic cancer, advancements in chemotherapy protocols, increased use of targeted therapies, a surge in the occurrence of pancreatic cancer, the establishment of combined treatment plans, and improvements in supportive care choices.

What will be the locally advanced pancreatic cancer market size in the future?

Projected expansion in the locally advanced pancreatic cancer market, which is anticipated to reach $1.57 billion by 2029, evidences a robust compound annual growth rate (CAGR) of approximately 10.5%. Factors attributing to this significant growth over the predicted period include greater understanding and knowledge of pancreatic cancer, bettered chemotherapy schedules, expanding use of targeted therapies, an escalation in pancreatic cancer cases, advancement of combined treatment protocols, and improved alternatives for supportive care. Foreseen trends for this period encompass progress in immunotherapy, expansion of targeted therapies, advanced precision radiation methods, improved diagnostic imaging procedures, increased utilization of minimally invasive surgical techniques, the incorporation of artificial intelligence into treatment design, as well as advancements in combined therapy protocols.

Get your locally advanced pancreatic cancer market report here!

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

What main drivers are fueling expansion in the locally advanced pancreatic cancer market?

The growth of locally advanced pancreatic cancer markets is expected to be fueled by the surge in tobacco usage. Tobacco, a plant whose leaves are utilized in substances like cigarettes and cigars, contains nicotine which is highly addictive and associated with serious health complications including cancer and cardiovascular diseases. Factors like easy availability, affordability, promotion of tobacco, societal sanction in some regions, and anxiety-induced smoking are escalating its consumption. A significant correlation exists between tobacco usage and the increased risk of locally advanced pancreatic cancer, leading to the high incidence of pancreatic tumors. As reported by the Global Action to End Smoking, a U.S. nonprofit entity committed to research to cease the smoking epidemic, in 2022, approximately 62.9 million adults in the U.S. used tobacco, placing it globally fourth and first in the Americas. Additionally, approximately 11.5% of U.S. adults (28.3 million) consumed cigarettes, with higher proportions in males (13.1%) compared to females (10.1%). Thus, the locally advanced pancreatic cancer market is experiencing growth due to the rise in tobacco usage.

What key areas define the segmentation of the global locally advanced pancreatic cancer market?

The locally advanced pancreatic cancer market covered in this report is segmented –

1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Surgery

2) By Route Of Administration: Oral, Injectables, Other Route Of Administrations

3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users

Subsegments:

1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy

2) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines

3) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)

4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure), Distal Pancreatectomy, Total Pancreatectomy

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

Who are the dominant players expanding their reach in the locally advanced pancreatic cancer market?

Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co

What are the key trends shaping the future of the locally advanced pancreatic cancer market?

Key players within the locally advanced pancreatic cancer market are concentrating their efforts on the creation of innovative products such as orphan drugs. These are aimed at improving treatment possibilities, enhancing patients’ outcomes, and addressing the unmet healthcare needs resulting from this aggressive disease. Orphan drugs, commonly used to treat rare diseases that affect a small population, are encouraged by regulatory authorities via perks such as tax reductions and exclusive market rights. Actuate Therapeutics Inc., an American biopharmaceutical firm, revealed in January 2025 that its new GSK-3ß inhibitor, Elraglusib, had been granted Orphan Drug Designation by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC) (a potential type of locally advanced pancreatic cancer). The acknowledgment of Elraglusib underlines its potential to address a significant need in the treatment of this serious cancer type, particularly in light of encouraging Phase 2 trial outcomes demonstrating noteworthy clinical progress and anti-tumor responses in patients with metastatic PDAC.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21214

Which regions are emerging as leaders in the locally advanced pancreatic cancer market?

North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Prenatal DNA Sequencing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/prenatal-dna-sequencing-global-market-report

Viral Vectors & Plasmid DNA Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

Breast Cancer Drugs Global Market Report 2025

https://thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the CAGR of the Locally Advanced Pancreatic Cancer Market Influence Its Overall Growth by 2034?

The market size for locally advanced pancreatic cancer has seen significant expansion in the recent past. From 2024 to 2025, it is projected to increase from $0.95 billion to $1.05 billion, with a compound annual growth rate (CAGR) of 10.9%. This growth during the historic period can be linked to a rise in awareness about pancreatic cancer, the implementation of improved chemotherapy methods, a surge in the utilization of targeted therapies, an increase in incidences of pancreatic cancer, the creation of combination treatment plans, and improvements in supportive care choices.

In the coming years, the local advanced pancreatic cancer market is anticipated to experience swift expansion. Growth projections indicate an increase to $1.57 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 10.5%. This significant growth during the forecast period can be primarily traced back to heightened cancer awareness, improved chemotherapeutic methods, increased usage of targeted therapies, and rising occurrences of pancreatic cancer. Further factors are the evolution of combined treatment protocols and improved options for supportive care. Key trends in the pipeline for this forecast period include progress in immunotherapy, creation of novel targeted therapies, advancements in precision radiation practices, improved diagnostic imaging techniques, preference for less invasive surgical procedures, integration of artificial intelligence in devising treatment plans, and advancements in treatment combination approaches.

Which Major Market Drivers Are Expected to Boost the Locally Advanced Pancreatic Cancer Market’s Growth Potential?

The growth of the markets for locally advanced pancreatic cancer is forecasted to be propelled by the escalating usage of tobacco. The tobacco plant’s leaves are utilized in the manufacturing of products like cigars and cigarettes. These products contain nicotine, an addictive substance that can lead to severe health complications such as heart disease and cancer. Factors that contribute to the increase in tobacco usage could be its easy accessibility, affordability, marketing of tobacco, its acceptance in certain social circles, and stress-induced smoking. The consumption of tobacco is a primary risk factor for the emergence of locally advanced pancreatic cancer as it leads to a rise in pancreatic malignancies. As per the research by the US-based nonprofit organization focused on ending the smoking epidemic, Global Action to End Smoking, it was reported in 2024 that in 2022, about 62.9 million American adults were using tobacco, placing the U.S. at 4th position globally and topmost in the Americas. Moreover, roughly 11.5% of American adults, equating to 28.3 million, were cigarette smokers, with the percentage being higher among men (13.1%) as compared to women (10.1%). Hence, the escalating usage of tobacco is facilitating the growth of the market for locally advanced pancreatic cancer.

Get Your Free Sample of the Global Locally Advanced Pancreatic Cancer Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

Who Are the Leading Companies Pioneering Change in the Locally Advanced Pancreatic Cancer Market?

Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co

What Are the Most Significant Trends Transforming the Locally Advanced Pancreatic Cancer Market Today?

Prominent firms in the locally advanced pancreatic cancer market are concentrating on the creation of innovative solutions such as orphan drugs, aiming to optimize treatment methods, enhance patient prognosis, and fulfil the unaddressed healthcare requirements related to this severe illness. Orphan drugs, targeted at treating rare conditions impacting a minimal population, enjoy encouragement from regulatory bodies through incentives like tax deductions and exclusive market rights, further facilitating their development. As an example, in January 2025, Actuate Therapeutics Inc., an American biopharmaceutical enterprise, declared that its Elraglusib, a novel GSK-3ß inhibitor, has been granted Orphan Drug Designation by both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for treatment of pancreatic ductal adenocarcinoma (PDAC) (a likely type of locally advanced pancreatic cancer). This acknowledgment underscores its potential to bridge a crucial gap in combating this grave cancer, particularly following encouraging Phase 2 trial outcomes that demonstrated substantial clinical progression and anti-tumor impacts in metastatic PDAC patients.

Get Instant Access to the Global Locally Advanced Pancreatic Cancer Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

What Are the Primary Segments of the Locally Advanced Pancreatic Cancer Market and Their Roles in Growth Dynamics?

The locally advanced pancreatic cancer market covered in this report is segmented –

1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Surgery

2) By Route Of Administration: Oral, Injectables, Other Route Of Administrations

3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users

Subsegments:

1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy

2) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines

3) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)

4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure), Distal Pancreatectomy, Total Pancreatectomy

Which Regions Are Leading the Charge in Locally Advanced Pancreatic Cancer Market Development?

North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Definition of the Locally Advanced Pancreatic Cancer Market Impacting Future Growth?

Locally advanced pancreatic cancer (LAPC) refers to a stage of pancreatic cancer where the tumor is confined to the pancreas and surrounding tissues but has not spread to distant organs. This cancer is usually not suitable for surgical removal due to its involvement with vital blood vessels or nearby structures.

Browse Through More Similar Reports By The Business Research Company:

Prenatal DNA Sequencing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/prenatal-dna-sequencing-global-market-report

Viral Vectors & Plasmid DNA Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

Breast Cancer Drugs Global Market Report 2025

https://thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: